Skip to main content
Clinical Trials/NCT01584622
NCT01584622WithdrawnNot Applicable

Clinical Evaluation of the CADence System in Detection of Coronary Artery Diseases

AUM Cardiovascular, Inc.7 sites in 1 countryStarted: July 1, 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
7
Primary Endpoint
Efficacy of CADence in detecting greater than or equal to 50% stenosis anywhere in the coronary tree.

Study Overview

Brief Summary

The purpose of the study is to evaluate the effectiveness of the CADence system, a non-invasive device, in detecting greater than or equal to 50% coronary stenosis anywhere in the coronary tree.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Over 18 years old
  • •Willing and able to give informed consent
  • •Indicated for angiography evaluation.

Exclusion Criteria

  • •Pregnant or nursing
  • •Presence of pacemaker/defibrillator
  • •Presence of artificial valve
  • •Presence of severe valve disease
  • •Presence of congenital heart defect
  • •Left Ventricular Assist Device (LVAD)
  • •Presence of a bypass graft
  • •Presence of scars on the site thorax areas
  • •Coarctation of the aorta
  • •Participation in trial within 30 days prior to collecting CADenceTM data
  • •Asthma with wheezing
  • •Inability to lie flat in the supine position
  • •Acute STEMI
  • •Heart Transplant
  • •Recent Cocaine Use

Outcomes

Primary Outcomes

Efficacy of CADence in detecting greater than or equal to 50% stenosis anywhere in the coronary tree.

Time Frame: within three months

The CADence System will be considered to have demonstrated effectiveness in detecting greater than or equal to 50% coronary artery stenosis anywhere in the coronary tree if the estimated sensitivity as compared to angiography is statistically higher than 70%.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials